Published • loading... • Updated
Ipsen to Acquire Memo Therapeutics AG, Adding First-in-Class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
The deal includes a 200 million euro upfront payment and could top 700 million euro if development and sales milestones are met.
- On Wednesday, Ipsen announced a definitive agreement to acquire Memo Therapeutics AG, focusing on potravitug, a first-in-class monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients.
- BK polyomavirus reactivation affects approximately 30% of kidney transplant patients within the first year, yet no approved targeted therapies exist, forcing clinicians to reduce immunosuppression and risking graft rejection and loss.
- In the Phase II SAFE KIDNEY II trial, biopsy-proven BK polyomavirus associated nephropathy declined from 51.2% to 31.6% in the treatment group by week 20, while the placebo group showed no change.
- Shareholders of Memo Therapeutics AG will receive €200 million at closing, with deferred payments tied to development and regulatory milestones pushing total potential consideration above €700 million, expected in Q3 2026.
- Ipsen plans to initiate the SAFE KIDNEY III trial later this year, while Memo Therapeutics AG transfers unrelated assets including the DROPZYLLA platform to a newly incorporated company, Memorises Bio, retained by shareholders.
Insights by Ground AI
14 Articles
14 Articles
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources14
Leaning Left3Leaning Right2Center5Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 30%
C 50%
R 20%
Factuality
To view factuality data please Upgrade to Premium
